KR102267495B1 - 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도 - Google Patents

미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도 Download PDF

Info

Publication number
KR102267495B1
KR102267495B1 KR1020190096031A KR20190096031A KR102267495B1 KR 102267495 B1 KR102267495 B1 KR 102267495B1 KR 1020190096031 A KR1020190096031 A KR 1020190096031A KR 20190096031 A KR20190096031 A KR 20190096031A KR 102267495 B1 KR102267495 B1 KR 102267495B1
Authority
KR
South Korea
Prior art keywords
polypeptide
slc1a5
mitochondrial
syndrome
mitochondria
Prior art date
Application number
KR1020190096031A
Other languages
English (en)
Korean (ko)
Other versions
KR20210017183A (ko
Inventor
한정민
유희찬
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to KR1020190096031A priority Critical patent/KR102267495B1/ko
Priority to PCT/KR2020/010489 priority patent/WO2021025527A1/fr
Publication of KR20210017183A publication Critical patent/KR20210017183A/ko
Application granted granted Critical
Publication of KR102267495B1 publication Critical patent/KR102267495B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020190096031A 2019-08-07 2019-08-07 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도 KR102267495B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020190096031A KR102267495B1 (ko) 2019-08-07 2019-08-07 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도
PCT/KR2020/010489 WO2021025527A1 (fr) 2019-08-07 2020-08-07 Polypeptide ciblant les mitochondries et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020190096031A KR102267495B1 (ko) 2019-08-07 2019-08-07 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도

Publications (2)

Publication Number Publication Date
KR20210017183A KR20210017183A (ko) 2021-02-17
KR102267495B1 true KR102267495B1 (ko) 2021-06-22

Family

ID=74502754

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020190096031A KR102267495B1 (ko) 2019-08-07 2019-08-07 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도

Country Status (2)

Country Link
KR (1) KR102267495B1 (fr)
WO (1) WO2021025527A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984636B2 (en) 2002-08-12 2006-01-10 Medical Research Council Mitochondrially targeted antioxidants
GB0526449D0 (en) * 2005-12-23 2006-02-08 Medical Res Council Polypeptide targeting
KR20120115511A (ko) * 2010-01-15 2012-10-18 교와 핫꼬 기린 가부시키가이샤 항시스템 ａｓｃ 아미노산 트랜스포터 ２（ａｓｃｔ２） 항체
PL2571532T3 (pl) * 2010-05-14 2017-10-31 Abbvie Inc Białka wiążące IL-1
WO2012174452A1 (fr) * 2011-06-17 2012-12-20 Shire Human Genetic Therapies, Inc. Ciblage mitochondrial et utilisation thérapeutique associée
TW201446800A (zh) * 2013-03-15 2014-12-16 Abbvie Inc 針對ＴＮＦα之雙特異性結合蛋白

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SLC1A5 isoform 3[Pan troglodytes], GenBank: PNI28894.1 (2018. 1. 19.)*

Also Published As

Publication number Publication date
KR20210017183A (ko) 2021-02-17
WO2021025527A1 (fr) 2021-02-11

Similar Documents

Publication Publication Date Title
JP7007423B2 (ja) 細胞透過性ペプチド、それを含んだコンジュゲート、及びそれを含んだ組成物
US11702671B2 (en) Importation of mitochondrial protein by an enhanced allotopic approach
US20230313190A1 (en) Compositions and Methods for Degradation of Misfolded Proteins
US8524683B2 (en) Method for decreasing cardiac using a nucleic acid molecule encoding a variant phosphatase inhibitor-1
US20180214565A1 (en) Peptide having cell membrane penetrating activity
TWI678374B (zh) 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
EP2776458B1 (fr) Polypeptides cytoprotecteurs issus du récepteur-1 activé par une protéase (par1) et procédés associés
AU2014228777B2 (en) BH4 stabilized peptides and uses thereof
EP2721060A2 (fr) Petits peptides efficaces pénétrant les cellules, dérivés de la toxine maurocalcine issue du scorpion
KR102267495B1 (ko) 미토콘드리아 타겟팅용 폴리펩타이드 및 그 용도
EP2368906A1 (fr) Facteur 1 associe a fas
EP2392585A2 (fr) Protéines de squelette pour aptamères de peptides recombinants

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant